We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

BioLeap Wins GlaxoSmithKline Contract to Design Novel Lead Compounds for Previously Intractable Targets

News   Sep 09, 2009

 
BioLeap Wins GlaxoSmithKline Contract to Design Novel Lead Compounds for Previously Intractable Targets
 
 
 

RELATED ARTICLES

‘Shortcut’ Transforms Terpene Biosynthesis in E. Coli

News

Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.

READ MORE

Yeast Model of Metabolic Disorders May Lead to Novel Therapies

News

Researchers suggests that the role of yeast, the world's most basic eukaryotic unicellular organism, may pave the way for the development of novel, more effective therapies for the treatment of metabolic disorders.

READ MORE

Concern Over Fake ISO 9001 Accreditation of Chinese Companies

News

A study concludes that fake ISO 9001 quality certificates are very widespread across Chinese companies and that the certification processes of the auditing companies lack credibility.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE